Phio Pharmaceuticals (NASDAQ: PHIO) stock jumped 91% yesterday then fell back some 25% after hours. Obviously it’s difficult to know exactly where the PHIO stock price is going to go next but we'd suggest that it might well continue to fade back gently. Not for any reason other than the trading pattern suggests so. Some new information comes to light, some get very excited, a momentum trade develops and then, as they all do, it fades away again. The information is both good and useful - but it’s still possible to get a little too excited by it.
The basic idea at Phio: “Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells” Proving that any of those work and being able to get them to market would be valuable, of course.

Phio Pharmaceuticals stock price from Google Finance
Which is where the new information comes in: “Phio Pharmaceuticals Corp shares are trading higher after the company announced the poster presentation of two preclinical studies of its INTASYL compound PH-894 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The first study shows that melanoma cells treated with its PH-894 compound make them more recognizable to the immune cells.” and then: “Specifically, the treatment results in an increase in the tumor marker MART-1 (Melanoma tumor-associated antigen) allowing for better recognition and potentially increased killing by T cells. Local treatment with PH-894 presents a strategy to decrease BRD4 expression and upregulate MART-1 expression to increase immune response to cancer cells while reducing toxicities associated with systemic therapies. This study supports further development of PH-894 for injectable solid tumor indications such as melanoma.”
So, potentially they’ve got something useful here. But this is also a corporate information release, not an approval from the FDA or anything. So it’s worth taking an interest in Phio over this but perhaps not that grand excitement of a doubling of the value of the company overall.



